Filter By Unselect All

Sub Category Unselect See All

Country Unselect See All

Companies Unselect See All

Selected Filter(s): Reset All

  • Category
  • Reset
  • Sub Category
  • Reset
  • Country
  • Reset

Contact

Clinical Development Services & Solutions

Clinical Trials >> Clinical Development / Phase IIb-IV >> Phase II / III

Chiltern provides the following services for Phase lllb - IV Post-marketing Late-stage programs: Post-approval GCP studies, Disease, product and pregnancy registries, Epidemiological studies, Restricted access and compassionate use programs, Retrospective and chart extraction studies, Risk

Contact

Human Repeat Insult Patch Test (HRIPT)

Clinical Trials >> Clinical Development / Phase IIb-IV >> Phase II / III

To determine the safety of topical products, RCTS provides a range of clinical testing procedures, including a broad range of in-use and patch studies. Human repeat insult patch tests (HRIPT) for contact sensitization/irritation and acute or cumulative patch tests irritation.

Contact

Phase II And Phase III Clinical Trials

Clinical Trials >> Clinical Development / Phase IIb-IV >> Phase II / III

At Nutrasource, we combine clinical expertise in the areas of nutrition, nutraceuticals and pharmaceuticals, as appropriate, to manage trials efficiently and effectively to support product investigations in support of a successful product launch.

Contact

Clinical Development Services

Clinical Trials >> Clinical Development / Phase IIb-IV >> Phase II / III

Our experience, support systems and infrastructure enable us to provide the highest level of program management and clinical development services for Phase II-IIIb clinical trials.

Contact

Phase ll-lll

Clinical Trials >> Clinical Development / Phase IIb-IV >> Phase II / III

Your progress to Phases IIb and III will have twists and turns. PAREXEL’s worldwide infrastructure and end-to-end expertise can help you optimize your studies and implement pivotal trials expeditiously.

Phase II & Phase III Services offer a broad range of data for the validation of drug entity for the global healthcare/ pharmaceutical industry. These services assay validation leading up to Phase I/II and III clinical trials, and help to navigate pharmaceutical companies through the often complex, regulatory challenges of the drug approval process. Clinical trial development of new medicinal products is often complex and challenging, and that quality and regulatory compliance are integral to the overall outcome of your clinical study, from IND, to NDA/BLA submission and all the way to commercialization. Combining scientific leadership with disciplined execution, global access to patients and local / global regulatory expertise always speed up the compound on the path to approval. Full-time physicians provide strategic direction for study design and planning, train operations staff, work with primary investigators, provide medical monitoring, and meet with regulatory agencies. Trial design and execution are two of the major standpoints for a CRO to conduct these trials at key sites globally. Close collaborations and ongoing programs with high recruiting sites at academic, network, and independent centers (GCP Compliant) with in house contract attorneys to expedite contract negotiations and final executions are the signs of a good CRO.Proprietary, integrated clinical study management technology platform facilitates efficient execution of global trials with personnel experienced in Data Safety Monitoring Committee management as well as providing on-going statistical support. Site selection process and protocol design is always dependant on the long term strategy of the pharmaceutical/ Biotech Company. Phase II – III studies across all major therapeutic areas, including immunotherapies, oncology and rare and orphan diseases are done with a strong focus on safety. Multiple software and technology platforms are used to deliver high quality data and robust biostatistics services, on time and without surprises. During the part of journey from Proof-of-Concept through regulatory submission, Phase II-III specialists optimize every step of clinical trials by every means possible. For the successful placement of multinational trials, CRO’s provide you with all relevant information, not only on epidemiology and suitable investigators, but also on the regulatory environment, health care system, local therapeutic guidelines, or potential competitive projects. International multicentre phase II and III trials are challenging for the sponsor, due to differences in language, health care systems, regulatory environments, medical practice, and cultural background. Appropriate technologies and IQ systems enables easy visualization of data and metrics at a study and programme level. Full data-related support, including clinical data management, biostatistics, statistical programming, medical writing and pharmacovigilance are also major components of clinical trials. Working with the right strategic partner during later stages of product development, can help manage cost, reduce risk and ensure all deadlines are met.

ABOUT
THE PAGE

COLLAPSE